These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 15613927)

  • 21. Recombinant factor VIIa: a review on its clinical use.
    Franchini M
    Int J Hematol; 2006 Feb; 83(2):126-38. PubMed ID: 16513530
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recombinant activated factor VII (NovoSeven): addition to replacement therapy in acute, uncontrolled and life-threatening bleeding.
    Mayo A; Misgav M; Kluger Y; Geenberg R; Pauzner D; Klausner J; Ben-Tal O
    Vox Sang; 2004 Jul; 87(1):34-40. PubMed ID: 15260820
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activated recombinant human coagulation factor VII (rFVIIa) therapy for abdominal bleeding in patients with inhibitory antibodies to factor VIII.
    Liebman HA; Chediak J; Fink KI; Galvez AG; Shah PC; Sham RL
    Am J Hematol; 2000 Mar; 63(3):109-13. PubMed ID: 10679799
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review.
    Levi M; Peters M; Büller HR
    Crit Care Med; 2005 Apr; 33(4):883-90. PubMed ID: 15818119
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recombinant factor VIIa in the treatment of bleeding.
    Midathada MV; Mehta P; Waner M; Fink LM
    Am J Clin Pathol; 2004 Jan; 121(1):124-37. PubMed ID: 14750250
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acquired isolated factor VII deficiency associated with severe bleeding and successful treatment with recombinant FVIIa (NovoSeven).
    Mullighan CG; Rischbieth A; Duncan EM; Lloyd JV
    Blood Coagul Fibrinolysis; 2004 Jun; 15(4):347-51. PubMed ID: 15166922
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Management of bleeding using recombinant factor VIIa in a patient suffering from bleeding tendency due to a lupus anticoagulant-hypoprothrombinemia syndrome.
    Holm M; Andreasen R; Ingerslev J
    Thromb Haemost; 1999 Dec; 82(6):1776-8. PubMed ID: 10613675
    [No Abstract]   [Full Text] [Related]  

  • 28. Ongoing NovoSeven trials.
    Erhardtsen E
    Intensive Care Med; 2002 Oct; 28 Suppl 2():S248-55. PubMed ID: 12404094
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Use of recombinant activated factor VII (NovoSeven) in the treatment of a patient with idiopathic thrombocytopenic purpura complicated with subarachnoid and parenchimatous hemorrhage].
    Vyhovs'ka IaI; Karol' IuS; Fedak LM; Tsytsyk OI
    Lik Sprava; 2004; (7):77-81. PubMed ID: 15724622
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Successful use of recombinant factor VIIa in pelvic fracture haemorrhage.
    Dhruva KK; Joel VD; Antony S; Vinodan K
    J Indian Med Assoc; 2006 Jan; 104(1):42, 44. PubMed ID: 16850866
    [TBL] [Abstract][Full Text] [Related]  

  • 31. "Off-license" use of recombinant activated factor VII.
    Ghorashian S; Hunt BJ
    Blood Rev; 2004 Dec; 18(4):245-59. PubMed ID: 15501553
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recombinant activated factor VII: panacea or passing fad?
    Parker RI
    Pediatr Crit Care Med; 2005 May; 6(3):379-80. PubMed ID: 15880015
    [No Abstract]   [Full Text] [Related]  

  • 33. Successful use of recombinant factor VIIa (NovoSeven) in children with compartment syndrome: two case reports.
    Alioglu B; Avci Z; Baskin E; Ozcay F; Tuncay IC; Ozbek N
    J Pediatr Orthop; 2006; 26(6):815-7. PubMed ID: 17065954
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The use of recombinant activated factor VII in the control of haemorrhage following blunt pelvic trauma.
    Udy A; Vaghela M; Lawton G; Sigston P
    Anaesthesia; 2005 Jun; 60(6):613-6. PubMed ID: 15918835
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is recombinant FVIIa the magic bullet in the treatment of major bleeding?
    Spahn DR; Tucci MA; Makris M
    Br J Anaesth; 2005 May; 94(5):553-5. PubMed ID: 15814804
    [No Abstract]   [Full Text] [Related]  

  • 36. Mechanism of action of recombinant activated factor VII: an update.
    Hedner U
    Semin Hematol; 2006 Jan; 43(1 Suppl 1):S105-7. PubMed ID: 16427375
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Life-threatening hemorrhage in neonates: management with recombinant activated factor VII.
    Veldman A; Fischer D; Voigt B; Beyer PA; Schlösser R; Allendorf A; Kreuz W
    Intensive Care Med; 2002 Nov; 28(11):1635-7. PubMed ID: 12415453
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The use of recombinant factor VIIa for bleeding in paediatric practice.
    Millar CG; Stringer MD; Sugarman I; Richards M
    Haemophilia; 2005 Mar; 11(2):171-4. PubMed ID: 15810920
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recombinant factor VIIa prophylaxis in a patient with severe congenital factor VII deficiency.
    Tcheng WY; Donkin J; Konzal S; Wong WY
    Haemophilia; 2004 May; 10(3):295-8. PubMed ID: 15086331
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A response to 'the use of recombinant activated factor VII in the control of haemorrhage following blunt pelvic trauma.
    Geoghegan J; Tasker L
    Anaesthesia; 2005 Nov; 60(11):1156-7; author reply 1157. PubMed ID: 16229713
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.